↓ Skip to main content

The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, June 2015
Altmetric Badge

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order
Published in
Journal of Experimental & Clinical Cancer Research, June 2015
DOI 10.1186/s13046-015-0179-9
Pubmed ID
Authors

Guohua Xie, Fang Xie, Ping Wu, Xiangliang Yuan, Yanhui Ma, Yunchuan Xu, Li Li, Ling Xu, Ming Yang, Lisong Shen

Abstract

The purpose of this study was to develop a cost-effective approach for the determination of EGFR and KRAS mutations in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) samples from Chinese patients based on a sensitive pyrosequencing (PS) technique. The NSCLC and CRC cell lines were tested to determine the limitation of detection and reproducibility of the PS method. In addition, 494 NSCLC and 1099 CRC patient samples were assayed by PS to evaluate the EGFR or KRAS mutation patterns according to the clinicopathological features. The PS assay was able to reproducibly detect as few as 2 % mutant alleles with excellent linearity. EGFR mutations were detected in 35.63 % of the NSCLC samples, and KRAS mutations were detected in 39.76 % of the CRC samples. EGFR mutations were more frequently observed to be significant by multivariate analysis in NSCLC patients who were 65 years old or younger (OR = 2.51), had a nonsmoking history (OR = 3.63), and adenocarcinoma (OR = 3.57), but not in females (OR = 0.64). KRAS mutations were more frequently detected in CRC patients who were female (OR = 1.64) and 50 years old or older (OR = 4.17), and had adenocarcinoma (OR = 2.41). This is the first extensive validation of PS on FFPE samples using the detection of EGFR exons 18-21 mutations and KRAS exon 2 mutations. Our results demonstrate the utility of PS analysis for the detection of somatic EGFR and KRAS mutations in clinical samples and provide important clinical and molecular characteristics of NSCLC and CRC from Chinese patients.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 3 18%
Researcher 2 12%
Professor 1 6%
Lecturer 1 6%
Student > Ph. D. Student 1 6%
Other 1 6%
Unknown 8 47%
Readers by discipline Count As %
Medicine and Dentistry 4 24%
Biochemistry, Genetics and Molecular Biology 1 6%
Pharmacology, Toxicology and Pharmaceutical Science 1 6%
Agricultural and Biological Sciences 1 6%
Nursing and Health Professions 1 6%
Other 0 0%
Unknown 9 53%